David Greene's  Instablog

David Greene
Send Message
Trading and investing full time for personal account and consulting with a money manager firm with assets of over $55 Million. Worked on Wall Street for 18 years at two wirehouses and one boutique investment banking firm. Investment discipline includes taking advantage of Wall Street's tendency... More
My blog:
  • Peer-Reviewed Article on CTT's Pain Managment Therapy to Be Published in Medical Journal 2 comments
    Apr 15, 2010 3:47 PM | about stocks: CTT-RETIRED, PMTI, ABT, BAX, HAE, JNJ, MDT, STJ, SYK, GE, PHG

    Competitive Technologies (NYSE Amex: CTT) announced yesterday (April 14) that the long- awaited open Phase II clinical study on the use of CTT's Calmare(NYSE:R) pain therapy with patients suffering from Chemotherapy-Induced Peripheral Neurapathy (CIPN) will be publlished in a medical journal.The company will announce which medical journal and which issue in the next few weeks.  A peer-reviewed study is deemed by medical professionals to be of sufficient interest and significance to warrant being published for the broader medical community--a very encouraging sign that CTT's technology showed benefits in treating patients with CIPN.
    The study was conducted by Dr.Thomas Smith, Endowed Professor for Palliative Care Research and Medical Director for the Thomas Palliative Care Unit at Massey Cancer Center at the University of Virginia, and Patrick Coyne, Clinical Director of the Thomas Palliative Care Services at Massey Cancer Center.

    CTT's Calmare(R) pain therapy medical device, a non-invasive treatment for chronic and cancer pain neuropathies reisistant to standard drug therapy programs, was the subject of the Phase II study which was initiated June 2009 . The last of the patients in the study received the standard 10-day treatment protocol in late November 2009.

    From the April 14 Press release: "The study examined the device's effect on pain associated with CIPN that can produce sharp pains in the hands and feet of cancer patients who are undergoing chemotherapy. This debilitating pain affects about 30 to 40 percent of cancer patients treated with chemotherapy ((editor's highlight) and typically develops into a classic stocking-and-glove pain that can last for many years." In other words, CIPN could be a huge market for CTT.


    Disclosure: Long CTT
Back To David Greene's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • Ruth Kocherhans
    , contributor
    Comments (3) | Send Message
    Very interesting technology, It appears this stock lacks exposure when they get it, it looks like a home run.
    16 Apr 2010, 10:30 AM Reply Like
  • David Greene
    , contributor
    Comments (147) | Send Message
    Author’s reply » I would never be so glib as to say that a stock would be a "home run". There are always bumps in the road that can make things take longer than expected. But, having said that, the delays that have encumbered CTT for the past year finally look to be in the past. Recognition of their medical technology by the broader medical community finally is coming to pass. And the orders are starting to flow.


    The curious thing about small cap stocks is that oftentimes the investor community does not accept good news from a company until the volume is much higher and the awareness of the company, too, is much higher (actually, both volume and awareness go hand in hand).


    The 52 Week High for CTT is about $2.80, and the average trading volume is creeping up. Institutions hold 12% of the shares outstanding--which usually is a good sign that bigger players are aware of the company and its progress.


    All in all, CTT could really begin to attract more investors when it becomes clearer to a larger group of investors that their medical technology not only works, but also that the fundamentals are set up to be dramatically improved in the near-term. When it comes down to it, you have to SELL and build cash flow to be successful. Not just have a efficacious therapy for chronic pain. Finally, it looks like the real sales are starting.
    19 Apr 2010, 11:22 AM Reply Like
Full index of posts »
Latest Followers


  • Digesting The GMO Food Controversy And What It Means For Your Investment Portfolio http://seekingalpha.com/a/1dh8b
    Jul 10, 2014
  • European markets cratered on Labor Day, setting the stage for a 250-300 point drop in the DOW when traders return on Tuesday.
    Sep 5, 2011
  • Competitive Technologies (CTTC, $1.75) for continued strength after chronic pain technology is highlighted on two TV morning shows tomorrow.
    Mar 14, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.